Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SQMXTJN Capsule versus atorvastatin for atherosclerosis immune regulation
ChiCTR1800019353Phase 4Recruiting
- Sponsor
- Guangzhou Hospital of Integrated Traditional and Western Medicine
- Start
- Jan 2018
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Shenqimaixintong Capsule and atorvastatin in atherosclerosis (2 arms), sponsored by Guangzhou Hospital of Integrated Traditional and Western Medicine. Primary endpoints: TLR-4, TLR-9 and 4 more. Started Jan 2018; status: recruiting.
02
Drugs
Shenqimaixintong Capsuleatorvastatin
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on ChiCTR1800019353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019353.